{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:51:44Z","timestamp":1793199104034,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26724-4","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:21:43Z","timestamp":1764325303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Queiroz","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Pimentel","family":"de Assump\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"26724_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"26724_CR2","unstructured":"Stomach cancer survival statistics. Cancer Res. UK (2015). https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/stomach-cancer\/survival"},{"key":"26724_CR3","unstructured":"Cancer Statistics, R. 1975\u20132014 - SEER Statistics. SEER https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/index.html"},{"key":"26724_CR4","doi-asserted-by":"publisher","unstructured":"Wagner, A. D. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. CD004064 https:\/\/doi.org\/10.1002\/14651858.CD004064.pub3 (2010).","DOI":"10.1002\/14651858.CD004064.pub3"},{"key":"26724_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick, F. et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022).","journal-title":"Ann. Oncol."},{"key":"26724_CR6","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group. J. Clin. Oncol. 24, 4991\u20134997 (2006).","journal-title":"J. Clin. Oncol."},{"key":"26724_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham, D. et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36\u201346 (2008).","journal-title":"N Engl. J. Med."},{"key":"26724_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12885-024-11980-w","volume":"24","author":"FCA de Moraes","year":"2024","unstructured":"de Moraes, F. C. A. et al. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: A meta-analysis of randomized clinical trials. BMC Cancer. 24, 240 (2024).","journal-title":"BMC Cancer"},{"key":"26724_CR9","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.2174\/1871520622666220418131935","volume":"22","author":"HF Ribeiro","year":"2022","unstructured":"Ribeiro, H. F. et al. CDC25B Inhibition by menadione: A potential new therapeutical approach. Anticancer Agents Med. Chem. 22, 2927\u20132932 (2022).","journal-title":"Anticancer Agents Med. Chem."},{"key":"26724_CR10","doi-asserted-by":"publisher","first-page":"175628481989543","DOI":"10.1177\/1756284819895435","volume":"13","author":"AB Bona","year":"2020","unstructured":"Bona, A. B. et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Th. Adv. Gastroenterol. 13, 1756284819895435 (2020).","journal-title":"Th. Adv. Gastroenterol."},{"key":"26724_CR11","doi-asserted-by":"publisher","first-page":"85393","DOI":"10.18632\/oncotarget.13381","volume":"7","author":"MF Leal","year":"2016","unstructured":"Leal, M. F. et al. YWHAE Silencing induces cell proliferation, invasion and migration through the up-regulation of CDC25B and MYC in gastric cancer cells: New insights about YWHAE role in the tumor development and metastasis process. Oncotarget 7, 85393\u201385410 (2016).","journal-title":"Oncotarget"},{"key":"26724_CR12","first-page":"316","volume":"53","author":"C Cojocel","year":"2006","unstructured":"Cojocel, C., Novotny, L. & Vachalkova, A. Mutagenic and carcinogenic potential of menadione. Neoplasma 53, 316\u2013323 (2006).","journal-title":"Neoplasma"},{"key":"26724_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10637-005-6731-2","volume":"23","author":"D Lim","year":"2005","unstructured":"Lim, D. et al. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New. Drugs. 23, 235\u2013239 (2005).","journal-title":"Invest. New. Drugs"},{"key":"26724_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF01202221","volume":"121","author":"M Tetef","year":"1995","unstructured":"Tetef, M. et al. Mitomycin C and menadione for the treatment of advanced Gastrointestinal cancers: A phase II trial. J. Cancer Res. Clin. Oncol. 121, 103\u2013106 (1995).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"26724_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","volume":"39","author":"RE Sexton","year":"2020","unstructured":"Sexton, R. E., Hallak, A., Diab, M. N., Azmi, A. S. & M. & Gastric cancer: A comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 39, 1179\u20131203 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"26724_CR16","first-page":"264","volume":"71","author":"S Joshi","year":"2021","unstructured":"Joshi, S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71, 264\u2013279 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"26724_CR17","doi-asserted-by":"publisher","first-page":"9421","DOI":"10.3390\/ijms24119421","volume":"24","author":"G Grizzi","year":"2023","unstructured":"Grizzi, G. et al. Circulating tumor DNA in gastric adenocarcinoma: Future clinical applications and perspectives. Int. J. Mol. Sci. 24, 9421 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"26724_CR18","doi-asserted-by":"publisher","first-page":"12758","DOI":"10.1038\/s41598-024-63305-3","volume":"14","author":"W Li","year":"2024","unstructured":"Li, W. et al. Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer. Sci. Rep. 14, 12758 (2024).","journal-title":"Sci. Rep."},{"key":"26724_CR19","doi-asserted-by":"publisher","first-page":"15144","DOI":"10.18632\/oncotarget.24540","volume":"9","author":"CTU Guimar\u00e3es","year":"2018","unstructured":"Guimar\u00e3es, C. T. U. et al. Liquid biopsy provides new insights into gastric cancer. Oncotarget 9, 15144\u201315156 (2018).","journal-title":"Oncotarget"},{"key":"26724_CR20","doi-asserted-by":"publisher","first-page":"220151","DOI":"10.1183\/16000617.0151-2022","volume":"31","author":"F Jin","year":"2022","unstructured":"Jin, F. et al. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis. Eur. Respir Rev. 31, 220151 (2022).","journal-title":"Eur. Respir Rev."},{"key":"26724_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ctrv.2009.03.004","volume":"35","author":"B Mostert","year":"2009","unstructured":"Mostert, B., Sleijfer, S., Foekens, J. A. & Gratama, J. W. Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 35, 463\u2013474 (2009).","journal-title":"Cancer Treat. Rev."},{"key":"26724_CR22","doi-asserted-by":"publisher","first-page":"828368","DOI":"10.3389\/fonc.2022.828368","volume":"12","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Clinical utility of Circulating tumor cells in patients with esophageal cancer. Front. Oncol. 12, 828368 (2022).","journal-title":"Front. Oncol."},{"key":"26724_CR23","doi-asserted-by":"publisher","first-page":"802188","DOI":"10.3389\/fonc.2021.802188","volume":"11","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. Clinical application of Circulating tumor cells and Circulating endothelial cells in predicting bladder cancer prognosis and neoadjuvant chemosensitivity. Front. Oncol. 11, 802188 (2021).","journal-title":"Front. Oncol."},{"key":"26724_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14737159.2018.1522251","volume":"18","author":"I Tinhofer","year":"2018","unstructured":"Tinhofer, I. & Staudte, S. Circulating tumor cells as biomarkers in head and neck cancer: Recent advances and future outlook. Expert Rev. Mol. Diagn. 18, 897\u2013906 (2018).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"26724_CR25","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1002\/cncr.28309","volume":"119","author":"Y Uenosono","year":"2013","unstructured":"Uenosono, Y. et al. Clinical significance of Circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer 119, 3984\u20133991 (2013).","journal-title":"Cancer"},{"key":"26724_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 \u2013 Update and clarification: From the RECIST committee. Eur. J. Cancer. 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"26724_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781\u2013791 (2004).","journal-title":"N Engl. J. Med."},{"key":"26724_CR28","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302\u20136309 (2008).","journal-title":"Clin. Cancer Res."},{"key":"26724_CR29","first-page":"631","volume":"4","author":"MP Wong","year":"2012","unstructured":"Wong, M. P. Circulating tumor cells as lung cancer biomarkers. J. Thorac. Dis. 4, 631\u2013634 (2012).","journal-title":"J. Thorac. Dis."},{"key":"26724_CR30","unstructured":"Technology - Cytelligen, Inc. http:\/\/cytelligen.com\/jsjs"},{"key":"26724_CR31","doi-asserted-by":"publisher","unstructured":"Shakoori, A. R. Fluorescence in situ hybridization (FISH) and its applications. Chromosome Struct. Aberrations. 343\u2013367. https:\/\/doi.org\/10.1007\/978-81-322-3673-3_16 (2017).","DOI":"10.1007\/978-81-322-3673-3_16"},{"key":"26724_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40169-015-0081-2","volume":"4","author":"PP Lin","year":"2015","unstructured":"Lin, P. P. Integrated EpCAM-independent Subtraction enrichment and iFISH strategies to detect and classify disseminated and Circulating tumors cells. Clin. Transl. Med. 4, 38 (2015).","journal-title":"Clin. Transl Med."},{"key":"26724_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1593\/tlo.12247","volume":"5","author":"FA Coumans","year":"2012","unstructured":"Coumans, F. A., Ligthart, S. T. & Terstappen, L. W. Interpretation of changes in Circulating tumor cell counts. Transl. Oncol. 5, 486\u2013491 (2012).","journal-title":"Transl Oncol."},{"key":"26724_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/374131a0","volume":"374","author":"DO Morgan","year":"1995","unstructured":"Morgan, D. O. Principles of CDK regulation. Nature 374, 131\u2013134 (1995).","journal-title":"Nature"},{"key":"26724_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4615-4253-7_10","volume":"4","author":"I Nilsson","year":"2000","unstructured":"Nilsson, I. & Hoffmann, I. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell. Cycle Res. 4, 107\u2013114 (2000).","journal-title":"Prog Cell. Cycle Res."},{"key":"26724_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.pai.0000213120.58472.57","volume":"15","author":"H Takahashi","year":"2007","unstructured":"Takahashi, H. et al. High labeling indices of cdc25B is linked to progression of gastric cancers and associated with a poor prognosis. Appl. Immunohistochem. Mol. Morphol. 15, 267\u2013272 (2007).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"26724_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41374-018-0157-x","volume":"99","author":"F Fei","year":"2019","unstructured":"Fei, F. et al. The subcellular location of Cyclin B1 and CDC25 associated with the formation of polyploid giant cancer cells and their clinicopathological significance. Lab. Invest. 99, 483\u2013498 (2019).","journal-title":"Lab. Invest."},{"key":"26724_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apcata.2004.08.028","volume":"280","author":"W Bonrath","year":"2005","unstructured":"Bonrath, W. & Netscher, T. Catalytic processes in vitamins synthesis and production. Appl. Catal. A. 280, 55\u201373 (2005).","journal-title":"Appl. Catal. A"},{"key":"26724_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cattod.2014.12.026","volume":"254","author":"M Florea","year":"2015","unstructured":"Florea, M., Marin, R. S., P\u0103l\u0103\u015fanu, F. M. & Nea\u0163u, F. P\u00e2rvulescu, V. I. Mesostructured vanadia\u2013alumina catalysts for the synthesis of vitamin K3. Catal. Today. 254, 29\u201335 (2015).","journal-title":"Catal. Today"},{"key":"26724_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10637-019-00810-7","volume":"38","author":"MEF Hegazy","year":"2020","unstructured":"Hegazy, M. E. F. et al. Vitamin K3 thio-derivative: A novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells. Invest. New. Drugs. 38, 650\u2013661 (2020).","journal-title":"Invest. New. Drugs"},{"key":"26724_CR41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.redox.2018.03.013","volume":"16","author":"D Ivanova","year":"2018","unstructured":"Ivanova, D. et al. Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect. Redox Biol. 16, 352\u2013358 (2018). Vitamin K.","journal-title":"Redox Biol."},{"key":"26724_CR42","first-page":"5246","volume":"8","author":"MH Lee","year":"2016","unstructured":"Lee, M. H. et al. Menadione induces G2\/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and Cyclin B1. Am. J. Transl. Res. 8, 5246\u20135255 (2016).","journal-title":"Am. J. Transl Res."},{"key":"26724_CR43","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41419-022-05350-2","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Liquid biopsy in gastric cancer: Predictive and prognostic biomarkers. Cell. Death Dis. 13, 903 (2022).","journal-title":"Cell. Death Dis."},{"key":"26724_CR44","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3748\/wjg.v30.i12.1680","volume":"30","author":"D D\u00edaz","year":"2024","unstructured":"D\u00edaz, D., Arco, C. & Fern\u00e1ndez Ace\u00f1ero, M. J. Ortega Medina, L. Liquid biopsy for gastric cancer: Techniques, applications, and future directions. World J. Gastroenterol. 30, 1680\u20131705 (2024).","journal-title":"World J. Gastroenterol."},{"key":"26724_CR45","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3390\/jcm10102108","volume":"10","author":"CG Lengyel","year":"2021","unstructured":"Lengyel, C. G. et al. The emerging role of liquid biopsy in gastric cancer. J. Clin. Med. 10, 2108 (2021).","journal-title":"J. Clin. Med."},{"key":"26724_CR46","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12885-024-11879-6","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y., Du, H., Wang, N., Wang, L. & Huang, Y. An update of clinical value of Circulating tumor DNA in esophageal cancer: A systematic review and meta-analysis. BMC Cancer. 24, 129 (2024).","journal-title":"BMC Cancer"},{"key":"26724_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.14715\/cmb\/2024.70.2.37","volume":"70","author":"Q Zheng","year":"2024","unstructured":"Zheng, Q. & Ge, H. The role of mir96 in predicting CTC status and prognostic evaluation in gastric cancer patients. Cell. Mol. Biol. (Noisy-le-grand). 70, 264\u2013274 (2024).","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"26724_CR48","doi-asserted-by":"publisher","first-page":"e854","DOI":"10.1634\/theoncologist.2018-0741","volume":"24","author":"EA Abdallah","year":"2019","unstructured":"Abdallah, E. A. et al. The potential clinical implications of Circulating tumor cells and Circulating tumor microemboli in gastric cancer. Oncologist 24, e854\u2013e863 (2019).","journal-title":"Oncologist"},{"key":"26724_CR49","first-page":"e926565","volume":"27","author":"D Ning","year":"2021","unstructured":"Ning, D. et al. Comparison of cellsearch and Circulating tumor cells (CTC)-Biopsy systems in detecting peripheral blood Circulating tumor cells in patients with gastric cancer. Med. Sci. Monit. 27, e926565 (2021).","journal-title":"Med. Sci. Monit."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26724-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:11:30Z","timestamp":1764328290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26724"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26724-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committee of the Ophir Loyola Hospital (Hospital Ophir Loyola - HOL) under the protocol number CAAE 90790818.4.1001.5550. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Written informed consent was obtained from all participants prior to their inclusion in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"During the preparation of this manuscript, the authors utilized ChatGPT, GPT-4o model developed by OpenAI., to enhance the readability and language of the text. Following the use of this tool, the authors thoroughly reviewed and edited the content as necessary and assume full responsibility for the final version of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"42640"}}